Tennessee Man Sues Boehringer for Pradaxa Injuries

Capers was first prescribed Pradaxa in 2011 to reduce the risk of suffering stroke and systemic embolism. He continued to take the drug until he was rushed to the hospital allegedly due to Pradaxa internal bleeding on October 3, 2012. 

While his life was saved with emergency care, Capers still suffers from permanent physical and emotional damage to this day over the incident. According to his Pradaxa lawsuit, at no point in time was Capers aware that internal bleeding was a possible side effect, nor were there any indications about this risk on the drug’s warning label. Capers is suing Boehringer for manufacturing, selling, distributing and marketing a dangerous drug. The charges include negligence, false advertising, misrepresenting a product, and concealing information.

Overview of Pradaxa Complications

Pradaxa (dabigatran etexilate) was first approved by the U.S. Food & Drug Administration (FDA) on October 19, 2010, and it was approved to prevent stroke and systemic embolism for patients who have non-valvular atrial fibrillation. It is only the second drug in the pharmaceutical history of the United States to be approved for this purpose. The drug is manufactured by Boehringer Ingelheim, and has been a wild success for the short time it has been released, reaching $1 billion in sales in the 2011 fiscal year. 

While Pradaxa has received wide praise for its success, the drug has put the company under litigation fire. Soon after Pradaxa was released, it was discovered that while the drug worked well, it possibly worked too well in its blood-thinning function, allegedly causing hundreds of injuries and deaths from uncontrollable internal bleeding. It was also from those injury reports that it was discovered Pradaxa had no remedy to halt uncontrollable bleeding, whereas uncontrollable bleeding related to Warfarin could be remedied with vitamin K. However, it was not until January 17, 2012 that Boehringer updated Pradaxa’s warning label to include the risk of hemorrhagic complications with no available reversal agent. 

Capers’ Pradaxa lawsuit is being transferred to multidistrict litigation centered in Southern Illinois, joining other plaintiffs who have suffered similar injuries.

The Pradaxa MDL is In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385, in the U.S. District Court for the Southern District of Illinois.

File a Pradaxa Injury Lawsuit Today

If you believe that you or a loved one have been the victim of a Pradaxa internal bleeding injury, you have legal options. Please visit the Pradaxa Internal Bleeding Class Action Lawsuit Investigation. There, you can submit your claim for a free legal review and if it qualifies for legal action, a seasoned Pradaxa lawyer will contact you for a free, no-obligation consultation. You will be guided through the litigation process at no out-of-pocket expenses or hidden fees. The Pradaxa attorneys working this investigation do not get paid until you do.